- Departments, Labs and Institutes
- Research Centers and Programs
- Cancer Advancement through Partnerships in Research and Infrastructure
The University of Puerto Rico and UT MD Anderson seek to address cancer health drivers through the development of clinical, research, outreach and educational activities that benefit both institutions. This collaborative agreement is supported by a Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) U54 grant from the National Cancer Institute (NCI).
This collaboration between University of Puerto Rico and UT MD Anderson was established in 2001 through an NCI Comprehensive Partnerships to Advance Cancer Health (CPACH) grant. A long-term goal of the relationship is to reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors by advancing interventions from research and evaluation in targeted populations to widespread adoption through systematic dissemination and implementation of evidence-based practices.
Main objectives of the collaboration
- Establish a comprehensive long-term mutually beneficial collaboration between the University of Puerto Rico System and UT MD Anderson
- Develop collaborations to share expertise in particular areas (research, clinical, infrastructure and management)
- Expand outreach activities across Puerto Rico and Texas
- Build and sustain a training, mentoring and career development pipeline
- Enhance each institution’s ability to apply for external grants that focus on eliminating cancer health drivers
U54 Summer Experience
A summer training program is available to college and medical trainees from the University of Puerto Rico System. Participants can explore biomedical research as it relates to cancer, as well as gain firsthand experiences and mentorship in basic, clinical or translational research.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at UT MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.